Axsome Therapeutics Inc
AXSM
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.89B
Close$
$23.38
90.3% downside
Current Fair Value
90.3% downsideOvervalued by 90.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.89 Billion |
|---|---|
| Enterprise Value | $12.80 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.68 |
| Beta | 0.6 |
| Outstanding Shares | 51,198,349 |
Return
| Return on Equity | -344.96% |
|---|---|
| Return on Assets | -26.39% |
| Return on Invested Capital | -58.29% |
Valuation & Multiples
| P/E Ratio | -67.16 |
|---|---|
| PEG | -777.94 |
| Price to Sales | 18.61 |
| Price to Book Ratio | 241.97 |
| Enterprise Value to Revenue | 18.08 |
| Enterprise Value to EBIT | -80.04 |
| Enterprise Value to Net Income | -68 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 3.97 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.79
Average shareholder expectationRevenue Estimate
$195.13 M
Average shareholder expectationNext Earnings Call
Expected Date
August 3, 2026
EPS Estimate
$-0.85
Average shareholder expectationRevenue Estimate
$221.75 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9390▲ 27.77% |
|---|---|
| Total Calls | 705,000▼ 6.35% |
| Total Puts | 662,000▲ 32.99% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 76.21%▲ 0.97% |
|---|---|
| Total Invested | $6.41B▼ 6.66% |
| Investors Holding | 429▲ 7.00% |
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...